Patterns of Outcome in Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma Treated Primarily with Radical Radiotherapy

Hao-Yue Lu, Anni Chen, I. Iankov, M. Min, R. Gowda, R. Mukherjee, D. Roos, H. Le
{"title":"Patterns of Outcome in Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma Treated Primarily with Radical Radiotherapy","authors":"Hao-Yue Lu, Anni Chen, I. Iankov, M. Min, R. Gowda, R. Mukherjee, D. Roos, H. Le","doi":"10.4172/2324-9110.1000232","DOIUrl":null,"url":null,"abstract":"Introduction: The aims of this study were to determine patterns of outcome and prognostic factors in human papilloma virus positive oropharyngeal squamous cell carcinoma (OPSCC+) treated primarily with radical radiotherapy. \nMaterials and methods: We identified 54 patients at a tertiary hospital in South Australia who received treatment with curative intent for OPSCC+ with radical radiotherapy ± chemotherapy or cetuximab from 1st January, 2010 to 31st  March, 2017. We explored the effect of patient, tumour and radiotherapy factors on treatment outcomes. The primary endpoint was overall survival and the secondary endpoint was disease-free survival. \nResults: The median age was 59, with most patients being male (82%). The majority had advanced disease (89% stage IV). The median follow-up was 22.5 months. The one-year and two-year overall survival and disease-free survival rates were 89% and 79% and 77% and 68% respectively. Active smoking during radiotherapy was associated with trends to shortened overall survival (p=0.084) and reduced time to recurrence (p˃0.1). However, there was no statistically significant relationship between any other patient, tumour or treatment factors and disease-free or overall survival. \nDiscussion: Despite advanced stage at presentation, radiotherapy ± concurrent systemic therapy results in favorable outcomes for OPSCC+. Active smoking during radiotherapy may compromise overall survival. We strongly recommend smoking cessation prior to commencing radiotherapy for OPSCC+. In addition, we note that smokers involved in de-intensification trials may be at increased risk of poor outcomes.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2324-9110.1000232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The aims of this study were to determine patterns of outcome and prognostic factors in human papilloma virus positive oropharyngeal squamous cell carcinoma (OPSCC+) treated primarily with radical radiotherapy. Materials and methods: We identified 54 patients at a tertiary hospital in South Australia who received treatment with curative intent for OPSCC+ with radical radiotherapy ± chemotherapy or cetuximab from 1st January, 2010 to 31st  March, 2017. We explored the effect of patient, tumour and radiotherapy factors on treatment outcomes. The primary endpoint was overall survival and the secondary endpoint was disease-free survival. Results: The median age was 59, with most patients being male (82%). The majority had advanced disease (89% stage IV). The median follow-up was 22.5 months. The one-year and two-year overall survival and disease-free survival rates were 89% and 79% and 77% and 68% respectively. Active smoking during radiotherapy was associated with trends to shortened overall survival (p=0.084) and reduced time to recurrence (p˃0.1). However, there was no statistically significant relationship between any other patient, tumour or treatment factors and disease-free or overall survival. Discussion: Despite advanced stage at presentation, radiotherapy ± concurrent systemic therapy results in favorable outcomes for OPSCC+. Active smoking during radiotherapy may compromise overall survival. We strongly recommend smoking cessation prior to commencing radiotherapy for OPSCC+. In addition, we note that smokers involved in de-intensification trials may be at increased risk of poor outcomes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人乳头状瘤病毒阳性口咽鳞状细胞癌主要用根治性放射治疗的结果模式
简介:本研究的目的是确定主要接受根治性放疗的人乳头瘤病毒阳性口咽鳞状细胞癌(OPSCC+)的预后模式和预后因素。材料和方法:2010年1月1日至2017年3月31日,在南澳大利亚一家三级医院接受根治性放疗±化疗或西妥昔单抗治疗的OPSCC+患者54例。我们探讨了患者、肿瘤和放疗因素对治疗结果的影响。主要终点是总生存期,次要终点是无病生存期。结果:中位年龄59岁,以男性为主(82%)。大多数为晚期疾病(89%为IV期)。中位随访时间为22.5个月。1年和2年总生存率和无病生存率分别为89%和79%,77%和68%。放疗期间主动吸烟与总生存期缩短(p=0.084)和复发时间缩短(p= 0.1)相关。然而,任何其他患者、肿瘤或治疗因素与无病生存期或总生存期之间没有统计学上的显著关系。讨论:尽管出现时已进入晚期,但放疗±同步全身治疗对OPSCC+的预后有利。放射治疗期间主动吸烟可能影响总体生存率。我们强烈建议在OPSCC+放疗前戒烟。此外,我们注意到参与去强化试验的吸烟者出现不良结果的风险可能会增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Influence of Long-term Abemaciclib, A New CDK 4/6 Inhibitor: Decrease in Liver Metastasis in a Patient Suffering from Metastatic Breast Cancer Monoclonal Antibodies Treatment Safe Combination of Cisplatinand Metformin Reverts theMalignant Ascites in a MouseModel to a Solid Tumor byDownregulation of ÎNp63 andInduces Tumor Dormancy via mTOR/ p21 Mechanism Hepatocellular CarcinomaPost Viral Hepatitis B and C:Application of the PrognosticScore of Singapore Iron Overload in the Setting of H63D Gene Mutation and Inrahepatic Cholangiocarcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1